systemic lupus erythematosus
Conditions
Interventions
Regularly taking hydroxychloroquine 200mg/d or 400mg/d for at least 3 consecutive months of treatment:None
Sponsors
Nanjing Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Willing to sign the informed consent form and follow the requirements of the research protocol, and the subjects can understand and complete the research questionnaire 2. Diagnosed with SLE according to the 1997 American College of Rheumatology Classification Criteria 3. Patients aged 18-60 years 4. Hydroxychloroquine 200 mg/day or 400 mg/day is taken regularly for treatment for at least 3 consecutive months
Exclusion criteria
Exclusion criteria: 1. Combined with other autoimmune diseases, such as rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease, etc. 2. Patients with a history of head and neck radiotherapy, hepatitis C, active AIDS, sarcoidosis, Graves disease, diabetes, combined anticholinergic drugs or other factors that may affect the diagnosis of the disease were excluded 3. Exclude patients who combine amiodarone, quinidine, propupazone, cimetidine, fluoxetine, telithromycin, clarithromycin, itraconazole, ketoconazole, indinavir and other hepatic drugs with strong enzyme inhibition or drugs such as Andriol and Diyusheng white tablets that may affect routine blood examination 4. Patients with severe organ damage or expected survival =1 mg·kg-1·d-1 prednisone or equivalent doses of other corticosteroids) were excluded Exclude patients with SLE crisis and those who need to use high-dose glucocorticoids (>= 1 mg·kg-1·d-1 prednisone or equivalent doses) 6. Patients with malignant tumors 7. Co-infected patients (including those with current and previous tuberculosis) 8. Combined pregnancy, Lactating patients 9. Exclude patients with insufficient or contaminated blood samples
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SLEDAI;whole blood concentration;genotype; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory indicators; | — |
Countries
China
Contacts
Public ContactXie Han
Nanjing Drum Tower Hospital
Outcome results
None listed